The enormous upfront cash payment made by Merck & Co., Inc. to Daiichi Sankyo Co., Ltd. as part of its licensing deal last week led some industry watchers to speculate whether it was, at $4bn, the largest ever seen in biopharma. A new Scrip analysis, using data from Evaluate Pharma and Biomedtracker, can now confirm that it is – just.
Key Takeaways
- The $4bn cash payment Merck made to Daiichi Sankyo is the largest ever licensing upfront fee
- The second largest was the $3
The upfront fee just pips that for the collaboration signed by Galapagos NV and Gilead Sciences, Inc. three years ago, though that deal turned out little short of disastrous after the main asset it covered had to be abandoned
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
